Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11151 - 11175 of 11594 in total
SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Investigational
Matched Description: … SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. …
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
Investigational
Matched Description: … Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety …
ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease).
Investigational
Matched Description: … ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal …
Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).
Investigational
Matched Description: … Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from _Bacillus Subtilis_. …
Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).
Investigational
Matched Description: … Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness …
SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
Investigational
Matched Description: … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid …
NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Investigational
Matched Description: … NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase …
Octopamine is structurally similar to norepinephrine. It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.
Experimental
Matched Description: … It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World …
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Matched Description: … Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of …
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer).
Investigational
Matched Description: … Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
Investigational
Matched Description: … Developed by Takeda, it is being investigated for the treatment of hemophilia A.[A259831] …
MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
Investigational
Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.
Investigational
Matched Description: … Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. …
Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.[A225691, A225696] This drug is used in the treatment of thrombocytopenia.
Investigational
Matched Description: … Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary …
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. …
MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Investigational
Matched Description: … MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase …
TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Investigational
Matched Description: … TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in …
Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Experimental
Matched Description: … Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. …
Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer).
Investigational
Matched Description: … Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing …
MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).
Investigational
Matched Description: … MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK …
QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (RHO) gene.
Investigational
Matched Description: … QR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant …
A product from the iodination of MONOIODOTYROSINE. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE). [PubChem]
Experimental
Matched Description: … A product from the iodination of MONOIODOTYROSINE. …
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
Experimental
Matched Description: … N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. …
Ultevursen is a single-stranded RNA-based oligonucleotide targeting exon 13 of the USH2A gene that encodes usherin. It was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.
Investigational
Matched Description: … Ultevursen is a single-stranded RNA-based oligonucleotide targeting exon 13 of the USH2A gene that encodes …
Displaying drugs 11151 - 11175 of 11594 in total